XOMA to Present at Upcoming Investor Conferences
21 Dezember 2021 - 01:30PM
XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator
playing a distinctive role in helping companies achieve their goal
of improving human health, announced today its Chief Executive
Officer, Jim Neal, will present at the following upcoming investor
conferences:
- Biotech Showcase 2022 held virtually
January 10-12 and January 17-19, 2022. Mr. Neal will hold a
fireside chat titled, “Royalty Licenses: An Economic Asset Often
Ignored.” on Monday, January 10, 2022 at 10:30 AM PT.
- H.C. Wainwright BioConnect Virtual
Conference held January 10-13, 2022. The presentation will be
available on demand beginning January 10, 2022 at 4:00 AM PT and
can be accessed at https://bit.ly/3DWWNs8. The presentation
can also be accessed by visiting the investor relations section of
the Company’s website at www.xoma.com. A replay of the
presentation will be available and archived on the site for 90 days
after the event.
About XOMA CorporationXOMA is a biotechnology
royalty aggregator playing a distinctive role in helping biotech
companies achieve their goal of improving human health. XOMA
acquires the potential future economics associated with
pre-commercial therapeutic candidates that have been licensed to
pharmaceutical or biotechnology companies. When XOMA acquires
the future economics, the seller receives non-dilutive,
non-recourse funding they can use to advance their internal drug
candidate(s) or for general corporate purposes. The Company
has an extensive and growing portfolio with more than 70 assets
(asset defined as the right to receive potential future economics
associated with the advancement of an underlying therapeutic
candidate). For more information about the Company and its
portfolio, please visit www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time,
growth of its portfolio of assets and its leadership. In some
cases, you can identify such forward-looking statements by
terminology such as “anticipate,” “intend,” “believe,” “estimate,”
“plan,” “seek,” “project,” “expect,” “may,” “will,” “would,”
“could,” or “should,” the negative of these terms or similar
expressions. These forward-looking statements are not a
guarantee of XOMA’s performance, and you should not place undue
reliance on such statements. These statements are based on
assumptions that may not prove accurate, and actual results could
differ materially from those anticipated due to certain risks
inherent in the biotechnology industry, including those related to
the fact that our product candidates subject to out-license
agreements are still being developed, and our licensees may require
substantial funds to continue development which may not be
available; we do not know whether there will be, or will continue
to be, a viable market for the products in which we have an
ownership or royalty interest; if the therapeutic product
candidates to which we have a royalty interest do not receive
regulatory approval, our third-party licensees will not be able to
market them, and the impact to the global economy as a result of
the COVID-19 pandemic. Other potential risks to XOMA meeting
these expectations are described in more detail in XOMA's most
recent filing on Form 10-Q and in other SEC filings. Consider
such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
beliefs and assumptions only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable
law.
EXPLANATORY NOTE: Any references to “portfolio”
in this press release refer strictly to milestone and/or royalty
rights associated with a basket of drug products in
development. Any references to “assets” in this press release
refer strictly to milestone and/or royalty rights associated with
individual drug products in development.
As of the date of this press release, all assets in XOMA’s
milestone and royalty portfolio are investigational
compounds. Efficacy and safety have not been
established. There is no guarantee that any of these assets
will become commercially available.
Investor
contacts: |
|
|
Juliane Snowden |
|
Justin Frantz |
XOMA |
|
Solebury Trout |
+1-646-438-9754 |
|
+1-973-441-9731 |
juliane.snowden@xoma.com |
|
jfrantz@soleburytrout.com |
Media contact: Kathy Vincent KV
Consulting & Management +1-310-403-8951
kathy@kathyvincent.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
Von Mär 2023 bis Mär 2024